Merck Manual

Please confirm that you are a health care professional

honeypot link

Microscopic Polyangiitis (MPA)


Alexandra Villa-Forte

, MD, MPH, Cleveland Clinic

Reviewed/Revised Jun 2022 | Modified Sep 2022
Topic Resources

Microscopic polyangiitis is a systemic necrotizing vasculitis without immune globulin deposition (pauci-immune) that affects mainly small vessels. It may begin as a pulmonary-renal syndrome with rapidly progressing glomerulonephritis and alveolar hemorrhage, but the pattern of disease depends on the organs affected. Diagnosis is made by clinical findings and sometimes confirmed by biopsy. Treatment, which depends on disease severity, includes corticosteroids and immunosuppressants.

Microscopic polyangiitis (MPA) is rare (about 13 to 19 cases/million). Pathogenesis is unknown. MPA affects small vessels and is pauci-immune (ie, immune globulin deposition is not seen on tissue biopsy), similar to granulomatosis with polyangiitis Granulomatosis with Polyangiitis (GPA) Granulomatosis with polyangiitis is characterized by necrotizing granulomatous inflammation, small- and medium-sized vessel vasculitis, and focal necrotizing glomerulonephritis, often with crescent... read more Granulomatosis with Polyangiitis (GPA) (GPA) and eosinophilic granulomatosis with polyangiitis Eosinophilic Granulomatosis with Polyangiitis (EGPA) Eosinophilic granulomatosis with polyangiitis is a systemic small- and medium-vessel necrotizing vasculitis, characterized by extravascular granulomas, eosinophilia, and tissue infiltration... read more Eosinophilic Granulomatosis with Polyangiitis (EGPA) (EGPA), which differentiates it from immune complex-mediated small-vessel vasculitides (eg, immunoglobulin A–associated vasculitis Immunoglobulin A–Associated Vasculitis (IgAV) Immunoglobulin A–associated vasculitis (formerly called Henoch-Schönlein purpura) is vasculitis that affects primarily small vessels. It occurs most often in children. Common manifestations... read more Immunoglobulin A–Associated Vasculitis (IgAV) —formerly known as Henoch-Schönlein purpura) and small-vessel cutaneous vasculitis Cutaneous Vasculitis Cutaneous vasculitis refers to vasculitis affecting small- or medium-sized vessels in the skin and subcutaneous tissue but not the internal organs. Cutaneous vasculitis may be limited to the... read more Cutaneous Vasculitis . MPA affects predominantly small vessels (including capillaries and postcapillary venules), unlike polyarteritis nodosa Polyarteritis Nodosa (PAN) Polyarteritis nodosa is a systemic necrotizing vasculitis that typically affects medium-sized muscular arteries and occasionally affects small muscular arteries, resulting in secondary tissue... read more , which affects medium-sized muscular arteries. Older literature (ie, before 1994) did not adequately distinguish between polyarteritis nodosa and MPA―alveolar hemorrhage and glomerulonephritis can occur in MPA but not in polyarteritis nodosa. Rarely, MPA can occur in association with hepatitis B.

Clinical manifestations resemble those of granulomatosis with polyangiitis except that granulomatous destructive lesions (eg, pulmonary cavitary lesions) are absent and the upper respiratory tract is usually affected minimally or not at all. In both disorders, antineutrophil cytoplasmic antibodies (ANCA) may be present.

Symptoms and Signs of MPA

Usually, a prodromal illness with systemic symptoms of fever, weight loss, myalgia, and arthralgia occurs. Other symptoms depend on which organs and systems are affected:

Diagnosis of MPA

  • Clinical findings

  • Tests for antineutrophil cytoplasmic antibodies and routine laboratory tests

  • Biopsy

Microscopic polyangiitis should be suspected in patients who have unexplained combinations of fever, weight loss, arthralgias, abdominal pain, alveolar hemorrhage, new-onset nephritic syndrome, new-onset multiple mononeuropathy, or polyneuropathy. Laboratory tests and sometimes x-rays are done, but the diagnosis is usually confirmed by biopsy.

Tests include complete blood count , erythrocyte sedimentation rate (ESR), C-reactive protein, urinalysis, serum creatinine, and tests for antineutrophil cytoplasmic antibodies (ANCA). ESR, C-reactive protein levels, and white blood cell and platelet counts are elevated, reflecting systemic inflammation. Anemia of chronic disease is common. An acute drop in hematocrit suggests alveolar hemorrhage or hemorrhage in the gastrointestinal tract. Urinalysis (to check for hematuria, proteinuria, and cellular casts) should be done, and serum creatinine should be measured periodically to check for renal involvement.

Immunofluorescence staining can detect ANCA; this test is followed by an enzyme-linked immunosorbent assay (ELISA) to check for specific antibodies. At least 60% of patients are ANCA-positive, usually perinuclear ANCA (p-ANCA) with antibodies against myeloperoxidase.

Biopsy of the most accessible involved tissue should be done to confirm vasculitis. Renal biopsy may detect focal segmental pauci-immune necrotizing glomerulonephritis with fibrinoid necrosis of the glomerular capillary wall, leading to formation of cellular crescents.

In patients with respiratory symptoms, chest imaging is done to check for infiltrates. Bilateral patchy infiltrates suggest alveolar hemorrhage even in patients without hemoptysis. CT is much more sensitive than x-ray.

If patients have dyspnea and bilateral infiltrates, bronchoscopy should be done immediately to check for alveolar hemorrhages and to exclude infection. Blood coming from both lungs and all bronchi, with more blood coming as the bronchoscope goes deeper in the airways, indicates active alveolar hemorrhage. Hemosiderin-laden macrophages appear within 24 to 72 hours after onset of hemorrhage and may persist for up to 2 months.

Treatment of MPA

  • When vital organs are affected, high-dose corticosteroids plus cyclophosphamide or rituximab

  • For less severe cases, corticosteroids plus methotrexate

Treatment for induction of remission Treatment Granulomatosis with polyangiitis is characterized by necrotizing granulomatous inflammation, small- and medium-sized vessel vasculitis, and focal necrotizing glomerulonephritis, often with crescent... read more Treatment is similar to that of granulomatosis with polyangiitis, but the need for maintenance therapy is less clearly established in microscopic polyangiitis. Cyclophosphamide given daily plus corticosteroids improves survival when vital organs are affected. Rituximab has been shown to be noninferior to cyclophosphamide for inducing remission of severe disease. Induction and maintenance regimens vary, and adjunctive therapies such as plasma exchange and pulse IV methylprednisolone may or may not need to be used.

Less severe cases may be managed with corticosteroids plus methotrexate.

Key Points

  • Microscopic polyangiitis is a rare small-vessel vasculitis.

  • Manifestations are variable and may include alveolar hemorrhage, multiple mononeuropathy, and glomerulonephritis.

  • Confirm the diagnosis by testing for antineutrophil cytoplasmic antibodies and by biopsy.

  • Treat with corticosteroids plus an immunosuppressant (eg, cyclophosphamide or rituximab for severe disease).

Drugs Mentioned In This Article

Drug Name Select Trade
Cyclophosphamide, Cytoxan, Neosar
RIABNI, Rituxan, RUXIENCE, truxima
Jylamvo, Otrexup, Rasuvo, RediTrex, Rheumatrex, Trexall, Xatmep
A-Methapred, Depmedalone-40, Depmedalone-80 , Depo-Medrol, Medrol, Medrol Dosepak, Solu-Medrol
NOTE: This is the Professional Version. CONSUMERS: View Consumer Version
quiz link

Test your knowledge

Take a Quiz!